Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate (ADC). Inotuzumab recognizes human CD22. The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of inotuzumab ozogamicin is due to the binding of the ADC to CD22-expressing tumor cells, followed by internalization of the ADC-CD22 complex, and the intracellular release of N-acetyl-gamma-calicheamicin dimethylhydrazide via hydrolytic cleavage of the linker. Activation of N-acetyl-gamma-calicheamicin dimethylhydrazide induces double-strand DNA breaks, subsequently inducing cell cycle arrest and apoptotic cell death.
During the treatment period, the pharmacodynamic response to BESPONSA was characterized by the depletion of CD22-positive leukemic blasts.
Cardiac Electrophysiology
In a randomized clinical study in patients with relapsed or refractory ALL, increases in QTcF of ≥ 60 msec from baseline were measured in 4/162 patients (3%) in the BESPONSA arm and 3/124 patients (2%) in the Investigator's choice of chemotherapy arm. Increases in QTcF of > 500 msec were observed in none of the patients in the BESPONSA arm and 1/124 patients (1%) in the Investigator's choice of chemotherapy arm. Central tendency analysis of the QTcF interval changes from baseline showed that the highest mean (upper bound of the 2-sided 90% CI) for QTcF was 15.3 (21.1) msec, which was observed at Cycle 4/Day 1/1 hour in the BESPONSA arm [see Warnings and Precautions (5.5)].
The mean Cmax of inotuzumab ozogamicin was 308 ng/mL. The mean simulated total AUC per cycle was 100,000 ng∙h/mL. In patients with relapsed or refractory ALL, steady-state drug concentration was achieved by Cycle 4. Following administration of multiple doses, a 5.3 times accumulation of inotuzumab ozogamicin was predicted by Cycle 4.
Distribution
N-acetyl-gamma-calicheamicin dimethylhydrazide is approximately 97% bound to human plasma proteins in vitro. In humans, the total volume of distribution of inotuzumab ozogamicin was approximately 12 L.
Elimination
The pharmacokinetics of inotuzumab ozogamicin was well characterized by a 2-compartment model with linear and time-dependent clearance components. In 234 patients with relapsed or refractory ALL, the clearance of inotuzumab ozogamicin at steady state was 0.0333 L/h and the terminal half-life (t½) was 12.3 days. Following administration of multiple doses, a 5.3 times accumulation of inotuzumab ozogamicin was predicted by Cycle 4.
Metabolism
In vitro, N-acetyl-gamma-calicheamicin dimethylhydrazide was primarily metabolized via nonenzymatic reduction. In humans, N-acetyl-gamma-calicheamicin dimethylhydrazide serum levels were typically below the limit of quantitation.
Specific Populations
The effect of intrinsic factors on inotuzumab ozogamicin pharmacokinetics was assessed using a population pharmacokinetic analysis unless otherwise specified. Age (18 to 92 years of age), sex, and race (Asian versus non-Asian [Caucasian, Black, and Unspecified]) had no clinically significant effect on the pharmacokinetics of inotuzumab ozogamicin. Body surface area was found to significantly affect inotuzumab ozogamicin disposition. BESPONSA is dosed based on body surface area [see Dosage and Administration (2.1)].
Patients with Renal Impairment
The clearance of inotuzumab ozogamicin in patients with mild renal impairment (creatinine clearance [CLcr; based on the Cockcroft-Gault formula] 60–89 mL/min; n=237), moderate renal impairment (CLcr 30–59 mL/min; n=122), or severe renal impairment (CLcr 15–29 mL/min; n=4) was similar to patients with normal renal function (CLcr ≥ 90 mL/min; n=402). The safety and efficacy of inotuzumab ozogamicin in patients with end stage renal disease with or without hemodialysis is unknown.
Patients with Hepatic Impairment
The clearance of inotuzumab ozogamicin in patients with mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN, or total bilirubin > 1.0–1.5 × ULN and AST any level; n=150) was similar to patients with normal hepatic function (total bilirubin/AST ≤ ULN; n=611). There is insufficient data in patients with moderate and severe hepatic impairment (total bilirubin > 1.5 ULN).
Pediatric Patients
The exposure of inotuzumab ozogamicin increases with decreasing body size at the recommended dosage. There was an approximately 30% increase in AUC of inotuzumab ozogamicin in pediatric patients 1 year and older compared with adults.
Drug Interactions
In vitro
Effect of Metabolic Pathways and Transporter Systems on BESPONSA
N-acetyl-gamma-calicheamicin dimethylhydrazide is a substrate of P-glycoprotein (P-gp).
Effect of BESPONSA on Metabolic Pathways and Transporter Systems
At clinically relevant concentrations, N-acetyl-gamma-calicheamicin dimethylhydrazide had a low potential to:
At clinically relevant concentrations, inotuzumab ozogamicin had a low potential to:
The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of inotuzumab ozogamicin.
In clinical studies of BESPONSA in patients with relapsed or refractory ALL, the immunogenicity of inotuzumab ozogamicin was evaluated using an electrochemiluminescence (ECL)‑based immunoassay to test for ADA. For patients whose sera tested positive for ADA, a cell-based assay was performed to detect neutralizing antibodies (NAb).
During a maximum 6 cycles of treatment period in clinical studies of BESPONSA in adult patients with relapsed or refractory ALL, 7/236 (3%) patients tested positive for ADA. No patients tested positive for NAb. In patients who tested positive for ADA, the presence of positive ADA did not affect clearance following inotuzumab ozogamicin treatment. Because of the low occurrence of ADA, the effect of these antibodies on safety and efficacy of inotuzumab ozogamicin is unknown.
During a maximum 4 cycles of treatment period in clinical Study WI203581 (ITCC-059) of BESPONSA in pediatric patients with relapsed or refractory ALL (n=51), no patients tested positive for ADA against inotuzumab ozogamcin.
Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate (ADC). Inotuzumab recognizes human CD22. The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of inotuzumab ozogamicin is due to the binding of the ADC to CD22-expressing tumor cells, followed by internalization of the ADC-CD22 complex, and the intracellular release of N-acetyl-gamma-calicheamicin dimethylhydrazide via hydrolytic cleavage of the linker. Activation of N-acetyl-gamma-calicheamicin dimethylhydrazide induces double-strand DNA breaks, subsequently inducing cell cycle arrest and apoptotic cell death.
During the treatment period, the pharmacodynamic response to BESPONSA was characterized by the depletion of CD22-positive leukemic blasts.
Cardiac Electrophysiology
In a randomized clinical study in patients with relapsed or refractory ALL, increases in QTcF of ≥ 60 msec from baseline were measured in 4/162 patients (3%) in the BESPONSA arm and 3/124 patients (2%) in the Investigator's choice of chemotherapy arm. Increases in QTcF of > 500 msec were observed in none of the patients in the BESPONSA arm and 1/124 patients (1%) in the Investigator's choice of chemotherapy arm. Central tendency analysis of the QTcF interval changes from baseline showed that the highest mean (upper bound of the 2-sided 90% CI) for QTcF was 15.3 (21.1) msec, which was observed at Cycle 4/Day 1/1 hour in the BESPONSA arm [see Warnings and Precautions (5.5)].
The mean Cmax of inotuzumab ozogamicin was 308 ng/mL. The mean simulated total AUC per cycle was 100,000 ng∙h/mL. In patients with relapsed or refractory ALL, steady-state drug concentration was achieved by Cycle 4. Following administration of multiple doses, a 5.3 times accumulation of inotuzumab ozogamicin was predicted by Cycle 4.
Distribution
N-acetyl-gamma-calicheamicin dimethylhydrazide is approximately 97% bound to human plasma proteins in vitro. In humans, the total volume of distribution of inotuzumab ozogamicin was approximately 12 L.
Elimination
The pharmacokinetics of inotuzumab ozogamicin was well characterized by a 2-compartment model with linear and time-dependent clearance components. In 234 patients with relapsed or refractory ALL, the clearance of inotuzumab ozogamicin at steady state was 0.0333 L/h and the terminal half-life (t½) was 12.3 days. Following administration of multiple doses, a 5.3 times accumulation of inotuzumab ozogamicin was predicted by Cycle 4.
Metabolism
In vitro, N-acetyl-gamma-calicheamicin dimethylhydrazide was primarily metabolized via nonenzymatic reduction. In humans, N-acetyl-gamma-calicheamicin dimethylhydrazide serum levels were typically below the limit of quantitation.
Specific Populations
The effect of intrinsic factors on inotuzumab ozogamicin pharmacokinetics was assessed using a population pharmacokinetic analysis unless otherwise specified. Age (18 to 92 years of age), sex, and race (Asian versus non-Asian [Caucasian, Black, and Unspecified]) had no clinically significant effect on the pharmacokinetics of inotuzumab ozogamicin. Body surface area was found to significantly affect inotuzumab ozogamicin disposition. BESPONSA is dosed based on body surface area [see Dosage and Administration (2.1)].
Patients with Renal Impairment
The clearance of inotuzumab ozogamicin in patients with mild renal impairment (creatinine clearance [CLcr; based on the Cockcroft-Gault formula] 60–89 mL/min; n=237), moderate renal impairment (CLcr 30–59 mL/min; n=122), or severe renal impairment (CLcr 15–29 mL/min; n=4) was similar to patients with normal renal function (CLcr ≥ 90 mL/min; n=402). The safety and efficacy of inotuzumab ozogamicin in patients with end stage renal disease with or without hemodialysis is unknown.
Patients with Hepatic Impairment
The clearance of inotuzumab ozogamicin in patients with mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN, or total bilirubin > 1.0–1.5 × ULN and AST any level; n=150) was similar to patients with normal hepatic function (total bilirubin/AST ≤ ULN; n=611). There is insufficient data in patients with moderate and severe hepatic impairment (total bilirubin > 1.5 ULN).
Pediatric Patients
The exposure of inotuzumab ozogamicin increases with decreasing body size at the recommended dosage. There was an approximately 30% increase in AUC of inotuzumab ozogamicin in pediatric patients 1 year and older compared with adults.
Drug Interactions
In vitro
Effect of Metabolic Pathways and Transporter Systems on BESPONSA
N-acetyl-gamma-calicheamicin dimethylhydrazide is a substrate of P-glycoprotein (P-gp).
Effect of BESPONSA on Metabolic Pathways and Transporter Systems
At clinically relevant concentrations, N-acetyl-gamma-calicheamicin dimethylhydrazide had a low potential to:
At clinically relevant concentrations, inotuzumab ozogamicin had a low potential to:
The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of inotuzumab ozogamicin.
In clinical studies of BESPONSA in patients with relapsed or refractory ALL, the immunogenicity of inotuzumab ozogamicin was evaluated using an electrochemiluminescence (ECL)‑based immunoassay to test for ADA. For patients whose sera tested positive for ADA, a cell-based assay was performed to detect neutralizing antibodies (NAb).
During a maximum 6 cycles of treatment period in clinical studies of BESPONSA in adult patients with relapsed or refractory ALL, 7/236 (3%) patients tested positive for ADA. No patients tested positive for NAb. In patients who tested positive for ADA, the presence of positive ADA did not affect clearance following inotuzumab ozogamicin treatment. Because of the low occurrence of ADA, the effect of these antibodies on safety and efficacy of inotuzumab ozogamicin is unknown.
During a maximum 4 cycles of treatment period in clinical Study WI203581 (ITCC-059) of BESPONSA in pediatric patients with relapsed or refractory ALL (n=51), no patients tested positive for ADA against inotuzumab ozogamcin.
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.